Claims

1. A conjugate of Formula (IM)

$$Ab - (G^A–J^A–D^M)_k \qquad (IM)$$


or a pharmaceutically acceptable salt thereof, wherein

Ab is an antibody or antigen-binding fragment thereof,

k is an integer from 1 to 10,


each G^A is independently a conjugation group conjugated to the antibody or antigen-binding fragment thereof,

each D^M is



,


each J^A is independently a group of Formula (IMA)






(IMA),

E is $(CH_2)_{n1}$, wherein n1 is 0, 1, 2 or 3,

R^1 is C_{1-4} alkyl or H,

R^2 is ,

X is $(CH_2)_{n2,}$ ,  or , wherein n2 and n4 are 0, 1, 2 or 3, n3 is 1, 2 or 3, and Q is O or NR^A, wherein R^A is H, C_{1-4} alkyl or C_{3-4} cycloalkyl,

Y is O or NR^B, wherein R^B is H, C_{1-4} alkyl or C_{3-4} cycloalkyl,

Z is $(CH_2)_{n5}$, wherein n5 is 0, 1, 2, 3, 4 or 5,

m is an integer from 2 to 17,

p is 1 or 0,

q is 1 or 0,

(G^A) indicates the point of attachment to G^A, and

(D^M) indicates the point of attachment to D^M.

2. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein m is 9, 10, 11, 12 or 13, and/or wherein R^1 is CH_3.


3. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in claim 1 or claim 2, wherein E is CH_2, and/or wherein X is CH_2.

4. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 3, wherein Y is O, and/or wherein n5 is 1, 2, 3, 4 or 5.

5. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 4, wherein Z is CH_2 or $(CH_2)_2$, and/or wherein p is 1.


6. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 5, wherein q is 1.

7. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein each J^A is a group of Formula (IMB)




(IMB).

8. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 7, wherein G^A is selected from




wherein R^K is H or CH_3, R^L is C_{1-6} alkyl, and $\diagup^*$ indicates the point of attachment to the antibody or antigen-binding fragment thereof.

9. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in claim 8, wherein G^A is



.

10. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in claim 1, wherein each (G^A–J^A–D^M) is



.

11. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 10, wherein k is an integer from 2 to 8.

12. A pharmaceutical composition comprising a conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 11, and a pharmaceutically acceptable excipient.


13. A conjugate of Formula (IM) or a pharmaceutically acceptable salt thereof, as claimed in any one of claims 1 to 11, for use in the treatment of cancer.

14. A compound of Formula (IIM)

$$G^B–J^B–D^M \qquad \text{(IIM)}$$

or a salt thereof, wherein G^B is a conjugation group for conjugation to an antibody or antigen-binding fragment thereof,


J^B is a group of Formula (IIMA)



(IIMA),

wherein D^M, E, R^1, R^2, X, Y, Z, m, p and q are as defined for a conjugate of Formula (IM) in any one of claims 1 to 6, (G^B) indicates the point of attachment to G^B, and (D^M) indicates the point of attachment to D^M.

15. A compound of Formula (IIM) or a salt thereof, as claimed in claim 14, wherein G^B is selected from



wherein X^1 is CH or N,


h is 0 or 1,

Hal is Cl, Br or I,

R^K is H or CH_3, and


R^L is C_{1-6} alkyl.

16. A compound of Formula (IIM) or a salt thereof, as claimed in claim 14 or claim 15, wherein G^B is



.

17. A compound of Formula (IIM) or a salt thereof, as claimed in claim 14, that is




,

(2S,3S,4S,5R,6S)-6-(4-((5S,8S,11S,12R)-11-((S)-sec-butyl)-12-(2-((S)-2-((1R,2R)-3-(((1S,2R)-1-hydroxy-1-phenylpropan-2-yl)amino)-1-methoxy-2-methyl-3-oxopropyl)pyrrolidin-1-yl)-2-oxoethyl)-5,8-diisopropyl-4,10-dimethyl-3,6,9-trioxo-2,13-dioxa-4,7,10-triazatetradecyl)-2-((3-(2-((3-((3-(2,5-dioxo-2,5-dihydro-1H-pyrrol-1-yl)propanamido)methyl)-1-(2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxaoctatriacontan-38-oyl)azetidin-3-yl)oxy)acetamido)propanamido)methyl)phenoxy)-3,4,5-trihydroxytetrahydro-2H-pyran-2-carboxylic acid, or a salt thereof.


18. A compound of Formula (IVM)

$$J^{IVM}–D^{M} \text{ (IVM)}$$

or a salt thereof, wherein J^{IVM} is a group of Formula (IVMA)



(IVMA),

wherein D^M, E, R^1, X, Y, m, p and q are as defined for a conjugate of Formula (IM) in any one of claims 1 to 6, R^{2A} is  , wherein R^{Q1} is H or R^{P1}, each R^{Q2} is independently H or R^{P2}, and R^{Q3} is H or R^{P3}, wherein R^{P1} is a carboxylic acid protecting group, each R^{P2} is independently an alcohol protecting group and R^{P3} is an amine protecting group, and (D^M) indicates the point of attachment to D^M.